Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.67 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.67 |
| ▸ | GRK5 | P34947 | 12/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.53 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364624 | 0.88 | PDGFRB (0.69) | PDGFRBFGFR1ALKABL1RET | |
| SCHEMBL5367680 | 0.87 | PDGFRB (0.70) | PDGFRBFGFR1ALKABL1RET | |
| SCHEMBL16486408 | 0.86 | PDGFRB (0.62) | PDGFRBFGFR1ALKABL1RET | |
| SCHEMBL16486440 | 0.86 | PDGFRB (0.62) | PDGFRBFGFR1ALKABL1RET | |
| SCHEMBL16490724 | 0.86 | PDGFRB (0.62) | PDGFRBFGFR1ALKABL1RET | |
| SCHEMBL16568041 | 0.86 | PDGFRB (0.62) | PDGFRBFGFR1ALKABL1RET | |
| SCHEMBL16490719 | 0.86 | PDGFRB (0.62) | PDGFRBFGFR1ALKABL1RET | |
| SCHEMBL16568627 | 0.86 | PDGFRB (0.62) | PDGFRBFGFR1ALKABL1RET | |
| SCHEMBL16486531 | 0.86 | PDGFRB (0.62) | PDGFRBFGFR1ALKABL1RET | |
| SCHEMBL16490721 | 0.86 | PDGFRB (0.62) | PDGFRBFGFR1ALKABL1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1247803-A2 | Indolinone compounds suitable for modulation of protein kinases | Sugen, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PDGFRB 52/4885FGFR1 112/4885ALK 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.